Cleave Biosciences, Inc.
Records under this name other than the patents Cleave Biosciences, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
Showing 1 to 5 of 5 · Back to Cleave Biosciences, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,062,026 | Fused pyrimidines and substituted quinazolines as inhibitors of p97 Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,475,824 | Fused Pyrimidines as Inhibitors of P97 Complex Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 10,010,554 | Fused Pyrimidines as Inhibitors of P97 Complex Formerly held Lapsed on the fee record Ended Jul 3, 2026 · Medium confidence | Lapsed on the fee record | Ended Jul 3, 2026 | Medium confidence |
| US 9,868,722 | Monocyclic pyrimidine/pyridine compounds as inhibitors of P97 complex Formerly held Lapsed on the fee record Ended Jan 16, 2026 · USPTO record | Lapsed on the fee record | Ended Jan 16, 2026 | USPTO record |
| US 8,865,708 | Methods and Compositions for Inhibition of the Transitional Endoplasmic Reticulum Atpase Lapsed on the fee record Ended Oct 21, 2022 · High confidence | Lapsed on the fee record | Ended Oct 21, 2022 | High confidence |